BIOMAT Database Logo BIOMAT Database Logo

Lisuride and pergolide in Parkinson's disease. 1983

A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes

UI MeSH Term Description Entries
D008090 Lisuride An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS). Lysuride Hydrogen Maleate,Methylergol Carbamide,Arolac,Cuvalit,Dopergin,Dopergine,Lisuride Hydrochloride,Lisuride Maleate,Lisuride Maleate (1:1),Lisuride Maleate, (8beta)-Isomer,Lisuride Mesylate,Lisuride Phosphate (1:1),Lisuride, (8alpha)-(+-)-Isomer,Lysenyl,Lysurid,Revanil,Carbamide, Methylergol,Hydrochloride, Lisuride,Hydrogen Maleate, Lysuride,Maleate, Lisuride,Mesylate, Lisuride
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010479 Pergolide A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. Celance,LY-127,809,LY-127809,Parkotil,Pergolide Mesylate,Permax,Pharken,LY127,809,LY127809,Mesylate, Pergolide
D004185 Disability Evaluation Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits. Disability Evaluations,Evaluation, Disability,Evaluations, Disability
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit

Related Publications

A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Pergolide and lisuride for Parkinson's disease.
November 1979, Lancet (London, England),
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Pergolide and lisuride in advanced Parkinson's disease.
January 1984, Advances in neurology,
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Lisuride in Parkinson's disease.
November 1979, Lancet (London, England),
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Pergolide in Parkinson's disease.
December 1983, Archives of neurology,
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
[Pergolide in Parkinson's disease].
January 1991, Archivos de neurobiologia,
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
[Oral lisuride in Parkinson's disease].
September 1985, Medicina clinica,
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Bromocriptine and lisuride in Parkinson's disease.
January 1984, Advances in neurology,
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Pergolide and lisuride for levodopa-induced oscillations.
September 1981, Lancet (London, England),
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Pergolide therapy in Parkinson's disease.
January 1984, Journal of neurology,
A E Lang, and M P Sheehy, and N P Quinn, and S Brincat, and C D Marsden, and D Parkes
Pergolide and selegiline for Parkinson's disease.
September 1989, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!